We identify and share funding opportunities as they arise to help advance MPT research and development. The items below are listed from the earliest to latest application due dates. We encourage you to browse below and contact us if you hear of any new opportunities.

Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). In addition to technologies, this opportunity is open to biobehavioral and behavioral/social studies, as well as applications involving pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-22-222, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-22-222
  • Open Date: 7 November 2022
  • Letters of Intent Due: N/A
  • Next Application Due: 7 December 2022

Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed)

This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will support the development of innovative, long-acting MPTs targeting HIV prevention and contraception in adolescent girls and young women. Specifically, this opportunity will support pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies, as well as biobehavioral and socio-behavioral research for potential MPT candidates. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-21-298, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-21-298
  • Open Date: 9 November 2021
  • Letters of Intent Due: 30 days prior to application receipt date
  • Next Application Due: 9 December 2022

Family Planning and Reproductive Health Methods APS

The United States Agency for International Development (USAID) is seeking to support the research, development, and introduction of technologies and approaches that better meet the needs of women as their sexual and reproductive health concerns change over time. This includes the development of multipurpose prevention technologies (MPTs) that address the simultaneous risks of unintended pregnancy, HIV, and other sexually transmitted infections (STIs)—particularly Herpes Simplex Virus (HSV) and Human Papillomavirus (HPV). Additional details can be found on the Round 4 call for concept papers at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: SOL-OAA-13-000024, then clicking on the opportunity number.

  • Funding Opportunity #: SOL-OAA-13-000024
  • Open Date: 15 January 2013
  • Closing Date: 14 January 2023
  • Round 5 funding not yet announced

Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 – Clinical Trial Not Allowed)

This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization – including potential MPT products. While aiming to position validated methods for clinical development, the award also encourages innovative ideas and supports early stage, high-risk projects lacking validation. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: RFA-HD-24-002, then clicking on the opportunity number.

  • Funding Opportunity #: RFA-HD-24-002
  • Open Date: 28 February 2023
  • Letters of Intent Due: 30 days prior to application receipt date
  • Next Application Due: 29 March 2023

Comprehensive Resources for HIV Microbicides and Biomedical Prevention (CRMP)

This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical prevention (nBP) strategies and products. The types of nBPs supported include, but are not limited to, topical microbicides, pre-exposure prophylaxis (PrEP) and Multipurpose Prevention Technologies (MPT’s) for the purpose of preventing HIV transmission and acquisition in adolescents, women, men and transgender individuals. Sponsors seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf. Data and reports are provided in a format that supports a regulatory filing. Additional details can be found here.

  • Who can use this resource?
    • Sponsors must have a defined need or gap that is delaying or blocking further advancement of their product to clinical testing and/or licensure.
    • Sponsors need preliminary data and/or regulatory agency input supporting a justification for the requested support.
    • If in support of a specific grant activity, the Sponsor needs to demonstrate a critical need to the advancement of the grant objectives that cannot be met by rebudgeting or administrative supplement, if applicable.  
  • How to get started: Follow the procedures for requesting access to NIAID contract services
  • Application Due: Rolling basis

MCI-BCM Sponsored Target Screening

This ongoing funding scheme offers the opportunity to utilize state-of-the-art facilities at Baylor College of Medicine to screen validated male contraceptive targets for small-molecule inhibitors using DNA-Encoded Chemistry Technology. Applications are accepted on an ongoing, rolling basis. Learn more and apply here.